0000819050false00008190502020-05-272020-05-27

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K 
________________

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) May 27, 2020
________________
BRICKELL BIOTECH, INC.
(Exact name of Registrant as specified in its charter)
Delaware 000-21088 93-0948554
(State or Other Jurisdiction
of Incorporation) 		(Commission File
Number) 		(IRS Employer
Identification No.)

5777 Central Avenue
Suite 102
Boulder, CO 80301
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (720) 505-4755
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s) 		Name of each exchange
on which registered
Common stock, par value $0.01 per share BBI The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 27, 2020, George Abercrombie informed Brickell Biotech, Inc. (the “Company”) of his resignation from the Company’s Board of Directors, effective immediately. In submitting his resignation, Mr. Abercrombie did not express any disagreement on any matter relating to the operations, policies or practices of the Company.
In connection with Mr. Abercrombie’s resignation, and in accordance with the Company’s By-Laws, the Board of Directors of the Company reduced the size of the Board from six members to five members.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.

104      Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 2, 2020 Brickell Biotech, Inc.
By:
/s/ Robert B. Brown
Name: Robert B. Brown
Title: Chief Executive Officer


Vical (NASDAQ:VICL)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Vical Charts.
Vical (NASDAQ:VICL)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Vical Charts.